BMY News and Press, Bristol-Myers Squibb Company From 04/29/24

2024-04-29 09:06:36 ET Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Conference Call April 25, 2024, 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Execut...

2024-04-29 08:51:30 ET Summary Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics...

2024-04-29 06:56:23 ET Bristol Myers Squibb ( NYSE: BMY ) and Repertoire Immune Medicines have entered a multi-year strategic collaboration to develop tolerizing vaccines for up to three autoimmune diseases.... Read the full article on Seeking Alpha For further detai...

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases PR Newswire Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune ...

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...

2024-04-27 09:29:58 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2024-04-27 08:15:00 ET Summary AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol-Myers Squibb has a strong pipeline and is undervalued. Both stocks offer po...

2024-04-27 06:39:22 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: What Moved Ma...

2024-04-26 14:32:03 ET More on Bristol, Sanofi, Takeda Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Sanofi 2024 Q1 - Results - Earnings Call Presentation Takeda s...

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy alone in cisplatin-eligible adults with unresectable or metastatic urothelial carcinoma If...